These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36599091)

  • 21. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of Nine Synthetic Cannabinoid Receptor Agonists Encountered in Clinical Casework: Major in vivo Phase I Metabolites of AM-694, AM-2201, JWH-007, JWH-019, JWH-203, JWH-307, MAM-2201, UR-144 and XLR-11 in Human Urine Using LC-MS/MS.
    Hutter M; Broecker S; Kneisel S; Franz F; Brandt SD; Auwarter V
    Curr Pharm Biotechnol; 2018; 19(2):144-162. PubMed ID: 29745330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and
    Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
    ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
    Patel M; Finlay DB; Glass M
    Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market.
    Brandon AM; Antonides LH; Riley J; Epemolu O; McKeown DA; Read KD; McKenzie C
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
    Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
    Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons.
    Rodrigues TB; Souza MP; de Melo Barbosa L; de Carvalho Ponce J; Júnior LFN; Yonamine M; Costa JL
    Forensic Toxicol; 2022 Jan; 40(1):119-124. PubMed ID: 36454481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic cannabinoid receptor agonists: classification and nomenclature.
    Potts AJ; Cano C; Thomas SHL; Hill SL
    Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007
    [No Abstract]   [Full Text] [Related]  

  • 36. A new cannabinoid receptor 1 selective agonist evading the 2021 "China ban": ADB-FUBIATA.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1639-1644. PubMed ID: 35570246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic cannabinoid receptor agonists and their human metabolites in sewage water: Stability assessment and identification of transformation products.
    Hehet P; Köke N; Zahn D; Frömel T; Rößler T; Knepper TP; Pütz M
    Drug Test Anal; 2021 Oct; 13(10):1758-1767. PubMed ID: 34272823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
    Malaca S; Tini A; Umani Ronchi F
    Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining Steric Requirements at CB
    Markham J; Sparkes E; Boyd R; Chen S; Manning JJ; Finlay D; Lai F; McGregor E; Maloney CJ; Gerona RR; Connor M; McGregor IS; Hibbs DE; Glass M; Kevin RC; Banister SD
    ACS Chem Neurosci; 2022 Apr; 13(8):1281-1295. PubMed ID: 35404067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro determination of the efficacy of illicit synthetic cannabinoids at CB
    Sachdev S; Vemuri K; Banister SD; Longworth M; Kassiou M; Santiago M; Makriyannis A; Connor M
    Br J Pharmacol; 2019 Dec; 176(24):4653-4665. PubMed ID: 31412133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.